MedImmune Inc., the research and development arm of global drug giant AstraZeneca PLC, is spinning out a new company named Viela Bio with plans to create 100 jobs within the next three to five years. As part of the launch, MedImmune said it raised $250 million from a consortium of investors led by Boyu Capital, 6 Dimensions Capital and Hillhouse Capital. AstraZeneca (NYSE: AZN) will remain the largest minority shareholder of Viela Bio, which will lease space on MedImmune’s campus in Gaithersburg. Viela…
from https://www.bizjournals.com/baltimore/news/2018/02/28/medimmune-announces-250-million-spinout-plan-to.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/171377553697
No comments:
Post a Comment